XML 25 R10.htm IDEA: XBRL DOCUMENT  v2.3.0.11
Goodwill And Other Intangibles
6 Months Ended
Jun. 30, 2011
Goodwill And Other Intangibles  
Goodwill And Other Intangibles

5. Goodwill and Other Intangibles

There were no changes in the goodwill carrying amount of $11.9 million during the six months ended June 30, 2011.

The components of our identifiable intangible assets were as follows:

 

     June 30, 2011      December 31, 2010  
     Gross
Carrying
Value
     Accumulated
Amortization
     Net
Carrying
Value
     Gross
Carrying
Value
     Accumulated
Amortization
     Net
Carrying
Value
 
     (in thousands)  

Patents

   $ 3,286       $ 1,451       $ 1,835       $ 3,761       $ 1,529       $ 2,232   

Trademarks and technology licenses

     1,251         771         480         1,271         735         536   

Customer relationships

     1,855         845         1,010         1,662         848         814   

Other intangible assets

     372         162         210         312         208         104   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total identifiable intangible assets

   $ 6,764       $ 3,229       $ 3,535       $ 7,006       $ 3,320       $ 3,686   
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

Intangible assets are amortized over their estimated useful lives, ranging from 1 to 15 years. Amortization expense amounted to approximately $0.2 million for each of the three months ended June 30, 2011 and 2010. Amortization expense amounted to approximately $0.5 million and $0.3 million for the six months ended June 30, 2011 and 2010. Amortization expense is included in general and administrative expense. Estimated amortization expense for the remainder of 2011 and each of the five succeeding fiscal years is as follows:

 

     (in thousands)  
2011            (remaining 6 months)    $ 474   
2012      828   
2013      760   
2014      589   
2015      374   
2016      266   

During the three months ended March 31, 2011, we determined that certain patents within our portfolio in the United States and Europe had no value based upon an analysis of expected economic benefits. As a result, we recorded an impairment charge of $0.1 million for the write-down of these patents. During the three months ended June 30, 2010, we incurred $0.1 million of impairment charges related to a customer relationship associated with our Biomateriali subsidiary based upon an analysis of expected economic benefits.